

18 September 2023

Investor Webinar Presentation

Osteopore Limited (ASX: OSX; Osteopore or Company), is an ASX-listed and Singapore-based global regenerative medicine company, specialising in the 3D printing of biomimetic and bioresorbable implants. Osteopore's implants speed up the body's natural healing process, improving quality of life and reducing the overall cost of healthcare.

Osteopore is pleased to invite shareholders to an investor webinar on The Watchlist, scheduled on Tuesday 19th September 2023, at 12:00 pm AEST/10:00 am AWST.

Executive Chairman, Mark Leong will provide an update on the Company's strategy for the Chinese market, its global expansion status, and the recent signing of a binding memorandum of understanding (MoU) with Temasek-linked InnoVentures Inc.

Following the presentation, attendees will have the opportunity to pose questions to Mr. Leong during a moderated Q&A session. The webinar can be seen LIVE via Zoom. Attendees can register via the link below. A recorded copy will be made available following the event.

https://us02web.zoom.us/webinar/register/WN_2c9lxYzPRFWM9bkGTwmccQ

ENDS

This announcement dated 18 September 2023 has been authorised for release to the ASX by the Board of Osteopore Limited.

For more information, please contact:

Mark Leong

Executive Chairman

Osteopore Limited

T: +65 9011 7009

E: mark_leong@osteopore.com

Isaac Stewart

Media & Investor Relations

Cannings Purple

T: +61 423 306 795

E: istewart@canningspurple.com.au



About Osteopore Limited

Osteopore Ltd. is a global medical technology company founded in Singapore and listed in Australia that commercialises products designed to enable natural bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent-protected scaffolds are manufactured using a proprietary manufacturing technique with a polymer that naturally dissolves over time to only allow natural and healthy bone tissue, significantly reducing the post-surgery complications commonly associated with permanent bone implants. Our 3D printing technology is unique to Osteopore.

Forward-Looking Statements

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices, or potential growth of Osteopore Limited, are or may be, forward-looking statements.

Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Depending on several factors, actual results may differ materially from those expressed or implied by these forward-looking statements.

